

Index

Note: Italicised f and t refer to figures and tables.

- acetaminophen, 173
 acupuncture, 153
 adnexal masses, 195–8
 afferent excitation, 140*t*
 agonists, 178
 Alcock's canal, 19
 allergic contact dermatitis, 52–3
 amitriptyline, 78, 90, 159, 172
 anal sphincter tears, 227
 anastrozole, 220
 androgen insensitivity syndrome (AIS), 122
 androgenic steroids, 197
 androgens, 182–4
 clinical data, 184
 pathophysiology of, 182–3
 physiology, 182–3
 anesthetics, 157, 159
 animal models, of dyspareunia, 199–205
 colitis, 203–4
 common pain behaviors, 201*t*
 endometriosis, 202–3
 evaluation of, 199–200
 interstitial cystitis, 203
 parturition, 203–4
 urethral calculosis, 200
 uterine distension, 202
 uterine inflammation, 200–202
 vaginal distension, 202
 validity of, 204–5
 yeast-induced sensitization to touch, 204
 antagonists, 178
 anterior separation, 144
 antibiotics, 15, 70–71
 antidepressants, 78
 antiprogestins, 197
 aphthous ulcers, 35–6, 54
 aromatase inhibitors, 220
 atrophic vaginitis, 105–7. *See also*
 desquamative inflammatory vaginitis (DIV)
 diagnosis of, 106–7
 etiology of, 105
 hormonal factors in, 187–9
 sexual dysfunction in, 105–6
 treatment of, 107
 atrophic vulvovaginitis, 38
 baclofen, 159
 bacterial vaginosis, 95–8
 clinical features of, 96–7
 diagnosis of, 97
 epidemiology, 95–6
 management of, 97–8
 pathogenesis, 96
 vulvovaginal candidiasis, 99–102
 Bartholin glands, 18
 Beck Anxiety Inventory (BAI), 23
 Beck Depression Inventory II (BDI-II), 23
 Behcets disease, 54
 benzocaine, 157
 biofeedback, 11, 79, 153
The Body Human (television show), 253
 botulinum toxin, 159–60
 brain gut interactions, 139–40
 breast cancer patients, 220
 Burch procedure, 144
 burning vulva syndrome. *See*
 vulvodynia
 butoconazole, 102*t*
The Camera My Mother Gave Me (book), 253
 cancer patients, 218–21
 cancer-related sexual pain, 221
 evaluation of, 219
 local issues, 220
 multimodal therapeutic management, 221–2
 physical examination of, 219
 sexual dysfunction in, 219–20
 sexual history of, 218–9
 systemic issues, 220–21
Candida, 99–101
 candidiasis, vulvovaginal, 99–102
 clinical features of, 100–101
 diagnosis of, 101
 epidemiology, 99
 host factors, 100
 management of, 101
 pathogenesis of, 99–100
 treatment of, 101–2
 cannabinoids, 173, 259
 capsaicin, 157–8
 carbamazepine, 173
 cefotetan, 71*t*
 cefoxitin, 71*t*
 ceftiraxone, 71*t*
 cephalosporin, 71*t*
 Cesamet, 173
 chancroid, 68
 Changes in Sexual Functioning Questionnaire (CSFQ), 23
 childbirth, 224
 childhood sexual abuse, 139
Chlamydia trachomatis, 68–9, 72
 chronic pelvic pain (CPP), 72
 and dyspareunia, 9
 in irritable bowel syndrome, 138–9
 and sexual abuse, 139, 213–4
 chronic vulvar pain. *See* vulvodynia
 chronic vulvovaginal candidiasis, 38
 clindamycin, 71*t*

- clinical interview, 21–2
 clitoridectomy, 236*t*
 clitoris, 120, 181*f*
 clotrimazole, 102*t*
 codeine, 173
 cognitive behavioral therapy (CBT), 150–53
 colitis, 203–4
 combined oral contraceptives (COCs), 127
 cone snail research, 259
 congenital adrenal hyperplasia (CAH), 122
 contact dermatitis, 52–3
 contraceptives, 15
 Coopers ligament, palpation of, 144
 corticosteroids, 158–9
 cotton swab test, 18*f*
 Crohns disease, 36
 Cushings disease, 183
 cyclooxygenase-2 (COX-2), 133
 Cymbalta, 78
 cystourethroceles, 144

 Danazol, 127
 deep dyspareunia, 72
 dehydroepiandrosterone (DHEA), 180, 182–4
 Depo-Lupron, 197
 dermatologic assessment, 246
 dermatoses, vulvar, 49–55
 aphthous ulcers, 54
 Behcets disease, 54
 contact dermatitis, 52–3
 lichen planus, 51–2
 lichen sclerosus, 50–51
 lichen simplex chronicus, 53–4
 mucous membrane pemphigoid, 54–5
 overview, 49
 plasma cell vulvitis, 55
 vulvar examination, 49–50
 desipramine, 78
 desquamative inflammatory vaginitis (DIV), 107–10. *See also* atrophic vaginitis
 diagnosis of, 109
 epidemiology, 108
 etiology of, 108–9
 microscopic findings in, 109*f*
 overview of, 108–9
 treatment of, 109–10
 disinhibition, 140*t*
 docosahexaenoic acid (DHA), 132
 Doxepin, 159
 doxycycline, 71*t*
 duloxetine, 78, 173
 Dyadic Adjustment Scale (DAS), 23
 dyspareunia, 4–7
 animal models of, 199–205
 colitis, 203–4
 common pain behaviors, 201*t*
 endometriosis, 202–3
 evaluation of, 199–200
 interstitial cystitis, 203
 parturition, 203–4
 urethral calculosis, 200
 uterine distension, 202
 uterine inflammation, 200–202
 vaginal distension, 202
 validity of, 204–5
 yeast-induced sensitization to touch, 204
 assessment of, 5
 in cancer patients, 218–22
 and congenital anomalies of female genital tract, 119–22
 definitions of, 4, 9
 evaluation of, 14–20
 medical history, 14–15
 medication history, 15–17
 physical exam, 17–18, 28–30
 physical therapy, 27–31
 testing, 19–20
 and female sexual dysfunction, 6, 92*f*
 and fibroids, 196–7
 as individual and societal burden, 9–10
 infections in, 10
 and interstitial cystitis, 88–92
 multidisciplinary treatment of, 10–11
 new assessment and treatment, 11–12
 outcome issues, 11
 and ovarian mass, 196
 postpartum, 224–7
 anal sphincter tears, 227
 generalized pain, 226
 localized pain, 226
 minimizing trauma in, 227
 overview, 224
 and perineal trauma, 224–5
 physical therapy, 226
 prevention of, 226
 repair techniques, 226
 TENS unit therapy, 226
 treatment of, 226–7
 ultrasound, 226
 prevalence of, 4–7
 psychological aspects of, 209–10
 psychological evaluation of, 21–4
 clinical interview, 21–2
 quantifiable measures, 23–4
 self-administered measures, 22–3
 relationship aspects of, 209
 and sexual abuse, 213–6
 sexual aspects of, 208–9
 sexual distress in, 5–6
 study design, 4–5
 and vaginismus, 229
 and vaginitis, 95
 vulvar dermatoses in, 49–55
 in vulvodynia, 2

 econazole, 102*t*
 Effexor XR, 78
 Elavil, 78, 159
 endometriosis, 124–8
 animal model, 202–3
 diagnosis of, 126
 epidemiology of, 125
 etiology of, 124–5
 history of, 126
 imaging studies, 126
 laparoscopy, 126
 medical treatment of, 127
 overview of, 124
 physical examination of, 126
 surgical treatment of, 127–8
 estradiol, 184
 estrogens, 184–5
 clinical data, 185
 pathophysiology of, 184–5
 physiology of, 184–5
 topical, 158

 female genital cutting, 235–42
 culturally competent care, 240–42
 epidemiology, 235–6

- female genital cutting (*cont.*)
 medical outcomes, 236
 neurobiological outcomes, 236–7
 overview, 235
 psychosexual outcomes, 236–7
 surgical management, 237–40
 types of, 235, 236*t*
- female genital tract, 119–22
 congenital anomalies of, 119–22
 clitoris, 120
 vagina, 120–22
 vulva, 120
 early development of, 119
 genetic and chromosomal abnormalities, 122
- female sexual arousal disorder (FSAD), 15
- Female Sexual Distress Scale (FSDS), 23, 90
- female sexual dysfunction (FSD), 91–2
 and dyspareunia, 6
 in irritable bowel syndrome, 137–8
 and sexual abuse, 139
- Female Sexual Function Index (FSFI), 23
- fentanyl patch, 173
- fenticonazole, 102*t*
- fibroblast cell culture research, 259
- fibroids
 and dyspareunia, 196–7
 treatment of, 197
- Fitz Hugh Curtis syndrome, 132
- fluconazole, 102*t*
- functional magnetic resonance imaging, 259
- gabapentin, 79, 158, 172–3
- Gardnerella vaginalis*, 96
- generalized vulvodynia (GVD), 76–80
 epidemiology, 76
 etiology of, 76–7
 overview of, 76
 physical examination of, 77
 treatment of, 77–80
 biofeedback, 79
 injectable therapies, 79
 oral treatments, 78–9
 physical therapy, 79
- psychological aspects, 79–80
 topical treatment, 77–8
- genital examination, 29–30
- genital herpes, 66–8. *See also* sexually transmitted infections (STIs)
 clinical presentations, 66–7
 diagnostic testing of, 68
 treatment of, 68
 viropathology, 66
- gentamicin, 71*t*
- Glazer protocol, 30
- Golombok Rust Inventory of Sexual Satisfaction (GRISS), 23
- gonadotropin-releasing hormone agonists (GnRHa), 127
- Graves speculum, 18
- group cognitive-behavioral therapy (GCBT), 11–12
- Harts line, 18
- herpes, 66–8. *See also* sexually transmitted infections (STIs)
 clinical presentations, 66–7
 diagnostic testing of, 68
 treatment of, 68
 viropathology, 66
- herpes simplex virus (HSV), 35, 66
- hidradenitis suppurativa (HS), 57–63
 diagnosis of, 58–60
 epidemiology, 57–8
 historical background, 57
 overview of, 57
 treatment of, 60–63
 medical therapy, 60–61
 psychosocial issues, 61–3
 surgical management, 61
- histology, 19
- HIV positive patients, 71
- hormonal therapies, 197
- human papillomavirus (HPV), 159
- hydromorphone, 173
- hydroxyzine, 90
- hyperprolactinemia, 183
- hypnosis, 153
- hypoactive sexual desire disorder (HSDD), 15
- IMMPACT group, 256
- infection assessment, 246–7
- injectable therapy, 159–60
- anesthetics, 159
- botulinum toxin, 159–60
- corticosteroids, 159
- interferon, 159
- interferon, 159
- International Society for the Study of Vulvovaginal Disease (ISSVD), 255
- interstitial cystitis, 203
- Interstitial Cystitis Association (ICA), 253
- interstitial cystitis/painful bladder syndrome (IC/PBS), 88–92
 diagnosis of, 88–90
 etiology of, 88
 overview, 88
 and sexual dysfunction, 91–2
 treatment of, 90–91
- intrauterine devices (IUDs), 71
- invasive vulvar cancer, 39
- irritable bowel syndrome (IBS), 136–42
 brain gut interactions, 139–40
 chronic pelvic pain in, 138–9
 comorbid conditions and symptoms, 137
 conceptual model, 140*f*
 overview, 136–7
 Rome III diagnostic criteria for, 137*t*
 and sexual abuse, 214–5
 sexual dysfunction in, 137–9
- irritant contact dermatitis, 52–3
- itraconazole, 102*t*
- ketoconazole, 102*t*
- labia majora, 17
- labia minora, 18
- lamotrigine, 173
- laser-evoked potentials, 258
- leiomyomata, 196
- lichen planus, 37–8, 51–2, 146*f*
- lichen sclerosus, 36–7, 50–51
- lichen simplex chronicus (LSC), 37–8, 53–4, 146*f*
- lidocaine, 78, 157, 159, 173
- leiomyomas, 195–8
- Locke Wallace Marital Adjustment Test (LWMAT), 23
- Lyrica, 79

- mast cells, 176–8
 clinical significance of, 178
 functional role of, 177–8
 inflammatory response, 177
 neovascularization, 177–8
 neurogenic inflammation, 177
 neurogenic response, 177
 re-epithelialization, 177–8
 scarring, 178
 vascular response, 177
 importance of, 176
 morphology of, 176–7
 overview of, 176
- Mayer Roikitsansky Kuster Hauser (MRKH) syndrome, 121
- McCoy Female Sexuality Questionnaire (MFSQ), 23
- McGill Pain Questionnaire, 11
- McGill Melzack Pain Questionnaire (MPQ), 22
- medical history, 14–15, 28
- Medical Research Fund, 252
- medications, and dyspareunia, 15–17
- Medoc Thermal Genital Sensory Analyzer, 24
- Medoc Vibratory Sensory Analyzer, 24
- meperidine, 173
- methadone, 173
- methylprednisolone, 159
- metronidazole, 71*t*, 99
- miconazole, 102*t*
- mifepristone, 197
- Mirena IUD, 197
- Mittleshmertz, 196
- modified vestibulectomy, 162
- morphine, 173
- mucous membrane pemphigoid, 54–5
- Müllerian duct, 119
- muscle assessment, 246
- musculoskeletal exam, 29
- myofascial trigger point release, 83
- National Institutes of Health (NIH), 251–2, 256
- National Vulvodynia Association (NVA), 250–54
 advocates, 254
 career development award, 252
 educational information, 250
- healthcare provider referrals, 251
- lobbying for research funding, 251–2
- medical research fund, 252
- online support, 250–51
- partners, 254
- professional education, 252–3
- public awareness campaign, 253–4
- support network, 250–51
- Neisseria gonorrhoea*, 69, 72
- neovascularization, 177–8
- neural mobilization, 83–4
- neuralgia, pudendal, 112–6
 anatomy of, 112–4
 clinical features of, 112–6
 diagnosis of, 114–5
 etiology of, 114
 modification of activities in, 115
 neurophysiologic testing, 114
 overview, 112
 pharmacological measures, 115
 physical therapy treatment of, 115–6
- pudendal nerve block, 114–6
- pudendal nerve decompression, 116
- neurogenic inflammation, 177
- neurological assessment, 247
- Neurontin, 79
- nitroglycerin, 158
- nitroimidazole, 99
- noninfectious vaginitis, 105–10
 atrophic, 105–7
 diagnosis of, 106–7
 etiology of, 105
 sexual dysfunction in, 105–6
 treatment of, 107
- desquamative inflammatory, 107–10
 diagnosis of, 109
 epidemiology, 108
 etiology of, 108–9
 microscopic findings in, 109*f*
 overview of, 108–9
 treatment of, 109–10
- treatment of, 102–3
- Norpramin, 78
- nortriptyline, 78, 90, 172
- nysatin, 102*t*
- Office of Research on Women's Health (ORWH), 252
- O'Leary Sant Symptom and Problem Index (OSSOI), 89–90
- opioids, 173
- oral contraceptives, 15, 69, 197
- ovarian masses, 195–6
- ovarian suppression, 220
- ovulatory pain, 196
- oxycodone, 173
- pain, 199–200. *See also* dyspareunia
 animal models of, 199–205
 colitis, 203–4
 common pain behaviors, 201*t*
 endometriosis, 202–3
 evaluation of, 199–200
 interstitial cystitis, 203
 parturition, 203–4
 urethral calculosis, 200
 uterine distension, 202
 uterine inflammation, 200–202
 vaginal distension, 202
 validity of, 204–5
 yeast-induced sensitization to touch, 204
- behaviors, 201*t*, 205*t*
- injectable therapy, 158–60
 anesthetics, 159
 benefit of, 156
 botulinum toxin, 159–60
 corticosteroids, 158–9
 interferon, 159
 side effects and limitations, 157
- interference and comorbid problems, 21–2
- mediators, 21
- in pelvic floor dysfunction, 160
- properties, 21
- self-administered measures, 22–3
- topical therapy, 156–9
 anesthetics, 157
 benefit of, 156
 capsaicin, 157–8
 drug trials, 157
 estrogen, 158
 gabapentin, 158
 nitroglycerin, 158
 side effects and limitations, 157
 testosterone, 158
 tricyclic antidepressants, 158

- pain, vulvar, 169–74. *See also*
 dyspareunia
 classification, 170*t*
 injectable therapy, 158–60
 anesthetics, 159
 benefit of, 156
 botulinum toxin, 159–60
 corticosteroids, 159
 interferon, 159
 side effects and limitations, 157
 overview, 169
 pain management, 170–74
 in pelvic floor dysfunction, 160
 topical therapy, 156–9
 anesthetics, 157
 benefit of, 156
 capsaicin, 157–8
 drug trials, 157
 estrogen, 158
 nitroglycerin, 158
 side effects and limitations, 157
 testosterone, 158
- pain behaviors, 201*t*
- Pain Catastrophizing Scale (PCS), 22
- pain center, sexual, 244–50
 all-inclusive model, 248
 assessment and diagnostic testing, 246–7
 cash payment model, 247
 categories of pain etiologies, 244
 coordinating treatment in, 247
 goals, 244–5
 insurance model, 247–8
 integrated approach, 245–6
 mission statement, 244
 patient convenience items, 248
 physical setting, 246
 reimbursement and coding in, 247–8
 support services, 245
 team leaders, 245
 team members, 245
- painful bladder syndrome (PBS), 88–92
 diagnosis of, 88–90
 etiology of, 88
 overview, 88
 and sexual dysfunction, 91–2
 treatment of, 90–91
- Pamelor, 78
- parturition, 203–4
- patient advocacy, 250–54
- pelvic anatomy, 27–8
- pelvic floor, 30
 electromyographic assessment of, 30
 examination of, 30
 musculature, 30
- pelvic floor dysfunction (PFD), 19
 pain in, 160
 physical therapy treatment of, 82–6
 joint mobilization, 84
 myofascial trigger point release, 83
 neural mobilization, 83–4
 therapeutic exercises, 84–5
 visceral manipulation, 83
- pelvic floor rehabilitation, 150–53
- pelvic inflammatory disease (PID), 131–4. *See also* sexually transmitted infections (STIs)
 causes of, 69
 clinical features of, 70
 diagnosis of, 69–70, 133–4
 differential diagnosis of, 70
 dyspareunia, 131–3
 in HIV positive patients, 71
 incidence of, 69
 laparoscopy, 70
 long-term complications, 72
 chronic pelvic pain, 72
 deep dyspareunia, 72
 follow-up, 72
 prevention, 72
 tubal infertility, 72
 management of, 133–4
 antibiotics, 70–71
 outcomes/complications, 71–2
 partner notification, 71
 removal of IUDs, 71
- pelvic adhesions, 131–3
- pelvic pain in, 131–3
 and pregnancy, 71
 prevention of, 133
 symptoms of, 70
 tests, 70
- pelvic organ prolapse (POP), 143–8
 anterior defects, 144
 diagnosis of, 143–4
 overview, 143
 posterior defects, 145–6
 mucosal factors, 145–6
- parturition, 145
 perineum, 145
 uterine prolapse, 147
 vulvar effects of, 146–7
 cervical discharge, 146–7
 incontinence, 146
 perineal disruption, 146
 prolapse, 146–7
- Pelvic Pain and Urgency/Frequency Scale (PUF), 89
- pentosanpolysulfate sodium (PPS), 90
- perineal region, normal anatomy of, 181*f*
- perineal trauma, 224–5
- perineoplasty, 164
- Personality Assessment Inventory (PAI), 23
- physical exam, 28–30
 general observation, 28–9
 musculoskeletal exam, 29
 pelvic and genital exam, 29–30
 posture, 28–9
- physical therapy, 79
- physical therapy treatment, 82–6
 behavioral therapies, 85
 joint mobilization, 84
 myofascial trigger point release, 83
 neural mobilization, 83–4
 overview, 82
 pelvic floor retraining, 84–5
 spinal core stabilization, 84
 therapeutic exercises, 84–5
 visceral manipulation, 83
- PID Evaluation and Clinical Health (PEACH) study, 132
- plasma cell vulvitis, 55
- postpartum dyspareunia, 224–7.
See also dyspareunia
 minimizing trauma in, 227
 overview, 224
 and perineal trauma, 224–5
 prevention of, 226
 repair techniques, 226
 treatment of, 226–7
 anal sphincter tears, 227
 generalized pain, 226
 localized pain, 226
 physical therapy, 226
 TENS unit therapy, 226
 ultrasound, 226

- posture, 28–9
- potassium hydroxide (KOH) prep, 19
- potassium sensitivity test (PST), 90
- pregabalin, 79, 172
- pregnancy, and pelvic inflammatory disease, 71
- pressure pain measurement, 23–4
- Private Practice* (television show), 253
- progesterone, 185
- progestins, 127
- provoked vestibulodynia (PVD), 43–7
- causes of, 45–7
- acquired neuronal proliferation, 46*t*
- congenital neuronal hyperplasia, 47*t*
- hormonal changes, 46*t*
- pelvic floor dysfunction, 45*t*
- erythema of, 18*f*
- etiology of, 43–5
- evaluation of, 45
- hormonal factors in, 185–7
- medical treatment of, 45–6
- multidisciplinary treatment of, 47
- pathophysiology of, 162
- surgical therapy, 162–7
- complications, 165
- effect of patient selection, 165
- overview of, 46–7
- postoperative care, 164–5
- study design, 167
- success factors, 165–6
- surgical outcomes, 165–6
- surgical technique, 162–4
- vulvar vestibule, 43
- provoked vulvodynia, 2
- pseudohermaphroditism, 122
- psycho-behavioral assessment, 246
- psychological distress, 209–10
- psychotherapy, 150–53
- psychotropic drugs, 15
- pudendal nerve block, 115–6
- pudendal neuralgia, 112–6
- anatomy of, 112–4
- clinical features of, 112–6
- diagnosis of, 114–5
- etiology of, 114
- modification of activities in, 115
- neurophysiologic testing, 114
- overview, 112
- pharmacological measures, 115
- physical therapy treatment of, 115–6
- pudendal nerve block, 114–6
- pudendal nerve decompression, 116
- Q-tip test, 144
- quantitative sensory testing (QST), 23–4, 257, 258
- random controlled trials (RCTs), 256–8
- re-epithelialization, 177–8
- relationship adjustment, 22
- relationships and dyspareunia, 209
- research, 255–9
- basic research, 258
- comorbidity studies, 258
- diagnostic categories, 255, 258–9
- epidemiological research, 256
- fibroblast cell culture, 258–9
- laser-evoked potentials, 258
- QST profiling, 258
- random controlled trials, 256–8
- sexual dysfunction and relationships, 258
- treatment, 259
- Sativex, 173
- scarring, 178
- Schwann cells, 259
- selective norepinephrine reuptake inhibitors (SNRIs), 78, 173
- selective serotonin reuptake inhibitors (SSRIs), 78, 173
- self-administered measures, 22–3
- pain, 22
- psychological function, 23
- relationship adjustment, 23
- sexual function, 22–3
- serum testing, 19–20
- Sex and the City* (television show), 253
- sex hormone binding globulin (SHBG), 19–20
- sex steroids, clinical measurement of, 180–82
- sexual abuse, 213–6
- and chronic pelvic pain, 213–4
- factors in, 215
- and irritable bowel syndrome, 139, 214–5
- overview of, 213
- and pain, 215–6
- and urinary symptoms, 215
- and vulvodynia, 215
- sexual distress, 5–6
- sexual dysfunction, 91–2
- in cancer patients, 219–20
- in irritable bowel syndrome, 137–9
- and relationships, 258
- in vaginal atrophy, 105–6
- Sexual Function Questionnaire (SFQ), 23
- sexual pain center, 244–50
- all-inclusive model, 248
- assessment and diagnostic testing, 246–7
- cash payment model, 247
- categories of pain etiologies, 244
- coordinating treatment in, 247
- diagnostic codes, 248*t*
- goals, 244–5
- insurance model, 247–8
- integrated approach, 245–6
- mission statement, 244
- patient convenience items, 248
- physical setting, 246
- procedure codes, 248*t*
- reimbursement and coding in, 247–8
- support services, 245
- team leaders, 245
- team members, 245
- sexual pain disorders, 185–9
- atrophic vaginitis, 187–9
- in cancer patients, 218–22
- hormonal factors in, 180–89
- provoked vestibulodynia, 185–7
- sexual pain history, 16*t*
- Sexual Satisfaction Scale for Women (SSS-W), 23
- sexually transmitted infections (STIs), 66–72
- chancroid, 68
- genital herpes, 66–8
- lymphogranuloma venereum, 68
- overview of, 66–72
- pelvic inflammatory disease, 69–72
- syphilis, 68
- trichomoniasis, 68–9

- siRNA targeting, 259
- Skene glands, 18
- surgical therapy, 162–7
 complications, 165
 effect of patient selection, 165
 outcomes, 165–6
 postoperative care, 164–5
 study design, 167
 success factors, 165–6
 success rates, 166*f*
 techniques, 162–4
 vestibulectomy, 162
 vestibuloplasty, 162
- syphilis, 68
- systematically acting agents, 259
- systemic therapy, 220–21
- tamoxifen, 220
- terconazole, 102*t*
- testosterone, 158
- tioconazole, 102*t*
- toluidine blue test (TBT), 32
- topical drugs, 78–9
- topical therapy, 156–9
 anesthetics, 157
 benefit of, 156
 capsaicin, 157–8
 drug trials, 157
 estrogen, 158
 gabapentin, 158
 nitroglycerin, 158
 side effects and limitations, 157
 testosterone, 158
 tricyclic antidepressants, 158
- tramadol, 173
- transcutaneous electrical stimulations (TENS), 226
- trichomoniasis, 98–9
 clinical features of, 98
 diagnosis of, 98–9
 epidemiology, 98
 management of, 99
 pathophysiology of, 98
- Trichomoniasis vaginalis*, 68
- tricyclic antidepressants (TCAs), 78, 158, 172
- tubal infertility, 72
- Turner syndrome, 122
- ulcerative conditions, 34–40
 aphthous ulcers, 35–6
 atrophic vulvovaginitis, 38
 chronic vulvovaginal candidiasis, 38
 Crohn's disease, 36
 herpes simplex virus, 35
 invasive vulvar cancer, 39
 lichen planus, 37
 lichen sclerosus, 36–7
 lichen simplex chronicus, 37–8
 vulvar intraepithelial neoplasia, 38–9
 vulvar Paget's disease, 39–40
- ultrasound therapy, 226
- ureteral calculosis, 200
- urethral meatus, normal anatomy of, 181*f*
- urinary symptoms, 215
- uterine distension, 202
- uterine inflammation, 200–202
- uterine leiomyomata, 196
- uterine prolapse, 147
- The V Book*, 253
- vagina, 120–22
- vaginal atrophy, 105–6
 etiology of, 105
 sexual dysfunction in, 105–6
- vaginal delivery, 145
- vaginal distension, 202
- vaginismus, 229–32
 anxiety in, 230
 definitions of, 229
 and dyspareunia, 229
 etiology of, 230–31
 symptoms, 229
 treatment of, 231–2
 vicious cycle of, 231*f*
- vaginitis, 105–10
 atrophic, 105–7
 diagnosis of, 106–7
 etiology of, 105
 sexual dysfunction in, 105–6
 treatment of, 107
- desquamative inflammatory, 107–10
 diagnosis of, 109
 epidemiology, 108
 etiology of, 108–9
- microscopic findings in, 109*f*
 overview of, 108–9
 treatment of, 109–10
- noninfectious, 102–3, 105–10
- vaginosis, bacterial, 95–8
 clinical features of, 96–7
 diagnosis of, 97
 epidemiology, 95–6
 management of, 97–8
 pathogenesis, 96
 vulvovaginal candidiasis, 99–102
- Vagisil, 157
- venlafaxine, 78, 173
- vestibulectomy, 162
- vestibulodynia, provoked, 43–7
 causes of, 45–7
 acquired neuronal proliferation, 46*t*
 congenital neuronal hyperplasia, 47*t*
 hormonal changes, 46*t*
 pelvic floor dysfunction, 45*t*
 etiology of, 43–5
 evaluation of, 45
 hormonal factors in, 185–7
 medical treatment of, 45–6
 multidisciplinary treatment of, 47
 pathophysiology of, 162
 surgery for, 46–7
 surgical therapy, 162–7
 complications, 165
 effect of patient selection, 165
 postoperative care, 164–5
 study design, 167
 success factors, 165–6
 surgical outcomes, 165
 surgical procedures, 162
 surgical technique, 162–4
 vulvar vestibule, 43
- vestibuloplasty, 162
- video colposcope, 17
- visceral manipulation, 83
- vulva, 120
 anatomy of, 17*f*, 44*f*
 congenital anomalies, 120
 physical examination of, 49–50
 sensory exam of, 17
 ulcerative conditions, 34–40
 aphthous ulcers, 35–6
 atrophic vulvovaginitis, 38

- chronic vulvovaginal candidiasis, 38
- Crohn's disease, 36
- herpes simplex virus, 35
- invasive vulvar cancer, 39
- lichen planus, 37
- lichen sclerosus, 36–7
- lichen simplex chronicus, 37–8
- vulvar intraepithelial neoplasia, 38–9
 - vulvar Paget's disease, 39–40
- vulvagesiometer, 24
- vulvar dermatoses, 49–55
 - aphthous ulcers, 54
 - Behcet's disease, 54
 - contact dermatitis, 52–3
 - lichen planus, 51–2
 - lichen sclerosus, 50–51
 - lichen simplex chronicus, 53–4
 - mucous membrane pemphigoid, 54–5
- overview, 49
- plasma cell vulvitis, 55
 - vulvar examination, 49–50
- vulvar intraepithelial neoplasia (VIN), 38–9
- vulvar Paget's disease, 39–40
- vulvar pain, 169–74. *See also* dyspareunia
 - classification, 170*t*
 - injectable therapy, 159–60
 - anesthetics, 159
 - benefit of, 156
 - botulinum toxin, 159–60
 - corticosteroids, 158–9
 - interferon, 159
 - side effects and limitations, 157
 - management of, 170–74
 - overview, 169
 - in pelvic floor dysfunction, 160
 - topical therapy, 156–9
 - anesthetics, 157
 - benefit of, 156
 - capsaicin, 157–8
 - drug trials, 157
 - estrogen, 158
 - gabapentin, 158
 - nitroglycerin, 158
 - side effects and limitations, 157
 - testosterone, 158
- vulvar vestibulectomy, 162
- vulvar vestibulitis syndrome (VVS), 1–2
- vulvitis, 102–3
- vulvodynia, 1–3
 - vs chronic vulvar pain, 2–3
 - generalized, 76–80
 - biofeedback, 79
 - epidemiology, 76
 - etiology of, 76–7
 - history of term, 2
 - injectable therapies, 79
 - oral treatments, 78–9
 - overview of, 76
 - physical examination of, 77
 - physical therapy, 79
 - psychological aspects, 79–80
 - topical treatment, 77–8
 - history of, 1
 - major subtypes, 2
 - provoked vestibulodynia, 1
 - and sexual abuse, 215
 - treatment of, 150–53
 - acupuncture, 153
 - biofeedback, 153
 - cognitive behavioral therapy, 150–53
 - hypnosis, 153
 - pelvic floor rehabilitation, 150–53
 - psychotherapy, 150–53
 - vulvoscopic finding of, 34
- vulvodynia research, 255–9
 - basic research, 258
 - comorbidity studies, 258
 - diagnostic categories, 255, 258–9
 - epidemiological research, 256
 - fibroblast cell culture, 259
 - laser-evoked potentials, 258
 - QST profiling, 258
 - random controlled trials, 256–8
 - sexual dysfunction and relationships, 258
 - treatment, 259
- The Vulvodynia Survival Guide* (book), 253
- vulvoscopy, 32–41
 - findings, 33–40
 - aphthous ulcers, 35–6
 - atrophic vulvovaginitis, 38
 - chronic vulvovaginal candidiasis, 38
 - Crohn's disease, 36
 - herpes simplex virus, 35
 - invasive vulvar cancer, 39
 - lichen planus, 37
 - lichen sclerosus, 36–7
 - lichen simplex chronicus, 37–8
 - vulvar intraepithelial neoplasia, 38–9
 - vulvar Paget's disease, 39–40
 - vulvodynia, 34
 - normal finding on, 33–4
 - overview of, 17–18, 32–3
- vulvovaginal candidiasis, 99–102
 - clinical features of, 100–101
 - diagnosis of, 101
 - epidemiology, 99
 - host factors, 100
 - management of, 101
 - pathogenesis of, 100
 - treatment of, 101–2
- vulvovaginitis, 95–103
 - bacterial vaginosis, 95–8
 - complications of, 97*t*
 - differential diagnosis of, 96*t* and dyspareunia, 95
 - noninfectious, 102–3
 - trichomoniasis, 98–9
- wet mount and cultures, 19
- white blood cells (WBCs), 19
- Wolffian duct, 119
- Xylocaine, 78
- yeast-induced sensitization to touch (YIST), 204

